Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
Conditions: Glioma; Glioma, Malignant Interventions: Diagnostic Test: Resting State Functional Magnetic Resonance Imaging (rs-fMRI); Behavioral: Up-front Motor Rehabilitation; Drug: Up-front Chemotherapy Sponsors: University of Milan; University of Turin, Italy Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: BL-B01D1; Drug: Pemetrexed+Cisplatin or Carboplatin Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Conditions: Triple-Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: Eribulin; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Capecitabine Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Conditions: Non Small Cell Lung Cancer Metastatic; ALK Gene Mutation Interventions: Drug: Lorlatinib Sponsors: Centro di Riferimento Oncologico - Aviano Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)
Conditions: Refractory Lupus Nephritis Interventions: Biological: TAK-007; Drug: Chemotherapy Agents Sponsors: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Conditions: Relapsed/Refractory KMT2A-r Acute Leukemia; Relapsed/Refractory NUP98-r Acute Leukemia; Relapsed/Refractory NPM1-m Acute Leukemia Interventions: Drug: Ziftomenib; Drug: Cytarabine; Drug: Fludarabine Sponsors: LLS PedAL Initiative, LLC; Kura Oncology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
Conditions: Limited-stage Small-cell Lung Cancer Interventions: Drug: Tislelizumab; Drug: Carboplatin injection; Drug: Cisplatin injection; Drug: Etoposide injection Sponsors: Beijing Chest Hospital, Capital Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
Conditions: Advanced Breast Cancer Interventions: Drug: physician ' s choice of chemotherapy sequential Ribociclib combined with NSAI ±OFS; Drug: Ribociclib combined with NSAI±OFS Sponsors: The First Affiliated Hospital with Nanjing Medical University; Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
Conditions: Gastric Cancer Interventions: Drug: Tislelizumab; Drug: SOX/XELOX Sponsors: Xiangdong Cheng; Liaoning Tumor Hospital& Institute; Shanxi Province Cancer Hospital; Sichuan Cancer Hospital and Research Institute; The Second Affiliated Hospital of Harbin Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
Conditions: Cancer, Ovarian; Chemotherapy Effect; Calorie Deficiency; Fasting, Intermittent Interventions: Other: Fasting Mimicking Diet; Drug: Chemotherapy Sponsors: L-Nutra Inc; University of Tennessee Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Conditions: Advanced Gastric Cancer; Neoadjuvant Therapy; Multi-omics Analysis Interventions: Procedure: combination chemotherapy with Apatinib or Camrelizumab Sponsors: Fujian Medical University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
Conditions: Breast Cancer Interventions: Drug: cyclophosphamide , methotrexate , vinorelbine ,capecitabine Sponsors: Sun Yat-sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Conditions: Muscle-invasive Bladder Cancer Interventions: Other: neoadjuvant chemotherapy followed by radical cystectomy Sponsors: Yonsei University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
Conditions: Cholangiocarcinoma Interventions: Procedure: Resection/Ablation of tumor; Procedure: Palliative chemotherapy; Procedure: Neoadjuvant chemotherapy; Procedure: Stereotatic radiotherapy; Procedure: Best supportive care Sponsors: Rigshospitalet, Denmark Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
